Compare LyondellBasell Industries NV (LYB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Summit Therapeutics Inc — how do they compare? LyondellBasell Industries NV trades at $63.87 (market cap $20.67B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: LyondellBasell Industries NV is the larger of the two by market cap, and LyondellBasell Industries NV pays a 6.44% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LYB | SMMT | |
|---|---|---|
Market Cap | $20.67B | $12.06B |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $26.98 |
52-Week Low | $42.28 | $12.55 |
Enterprise Value | $32.26B | $11.39B |
Dividend Yield | 6.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell Industries (LYB) trades at $62.79, up 0.22% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $4.30 versus $3.44 estimated, driven by improved margins from supply disruptions. However, 2025 fundamentals show challenges, including a net loss of $745 million and negative profit margins, though cash flow from operations remains positive at $2.26 billion.
The stock offers potential upside to the $70.56 analyst consensus target, with 46% of analysts rating it a buy, but faces risks from volatile chemical markets and high debt. Investor sentiment is mixed amid earnings recovery signs and macroeconomic pressures on demand.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
